Evidence map›Paper›PMID 29109446›Full record

ArticleLeukemia2018

Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.

S C Nimmagadda, S Frey, B Edelmann, C Hellmich, L Zaitseva, G M König, E Kostenis, K M Bowles, T Fischer

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Biomedicines · 2021
    Article
  4. Article
  5. Rac GTPases in Hematological Malignancies.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

S C NimmagaddaDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.
S FreyDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.
B EdelmannDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.
C HellmichDepartment of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, Norwich, UK.
L ZaitsevaDepartment of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, Norwich, UK.
G M KönigInstitute of Pharmaceutical Biology, University of Bonn, Bonn, Germany.
E KostenisInstitute of Pharmaceutical Biology, University of Bonn, Bonn, Germany.
K M BowlesDepartment of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, Norwich, UK.
T FischerDepartment of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.
Otto-von-Guericke University Magdeburg · DENorwich Research Park · GBUniversity of Bonn · DEUniversity of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene RearrangementAgammaglobulinaemia Tyrosine KinaseCell LineCell SurvivalHumansLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia Proteinrac1 GTP-Binding ProteinAgammaglobulinaemia Tyrosine KinaseMyeloid-Lymphoid Leukemia Proteinrac1 GTP-Binding Protein

Identifiers

PMID29109446
PMCPMC5843904
OpenAlexW2767305793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.